AllSci News
Columbia investigates HPF1's role in PARP inhibitor bone marrow toxicity
Columbia University Health Sciences has received a USD 1.83 million NIH R01 grant from the National Cancer Institute to investigate how Histone PARylation...
Fred Hutch investigates how Par-4 eliminates dormant breast cancer cells
Fred Hutch Cancer Center has received a USD 1.8 million NCI R01 renewal to investigate how the tumor suppressor Par-4 regulates actomyosin contractility as...
University of Illinois advances multivalent ETEC vaccine designed to target both toxins and adhesins
University of Illinois Urbana-Champaign has received a USD 1.12 million NIAID R01 grant to advance MecVax, a multivalent subunit vaccine candidate targeting...
NIH funds Michigan State Uni study for antibody-switching mechanism linked to B cell lymphoma
Henry Ford Health + Michigan State University Health Sciences has received a USD 2.86 million NIH R01 grant from the National Institute of Allergy and...
Elicio's pancreatic cancer vaccine misses primary goal but hints at benefit in resected patients
A Phase II trial failure that may still open a door — but only if Elicio can secure financing before its cash runs out in Q4 2026.
Cellares raises USD 327m to scale automated cell therapy manufacturing globally
South San Francisco-based Cellares has extended its Series D financing to USD 327 million following a USD 50 million growth equity investment from Prime...
Alvotech raises USD 152m to advance biosimilar pipeline and shore up balance sheet
Iceland-based Alvotech (Nasdaq: ALVO) announced the pricing of a combined underwritten public offering and concurrent private placement totaling...
Aplagon expands APAC into kidney disease complication with EUR 4.8m financing round
Finland-based Aplagon Oy has closed a EUR 4.8 million (approximately USD 5.6 million) financing round to fund a new Phase II clinical programme in...
Bayer’s Ambelvist approved as lowest-dose gadolinium contrast agent in US
Bayer announced receipt of US FDA approval for Ambelvist (gadoquatrane), a macrocyclic gadolinium-based contrast agent (mGBCA) for contrast-enhanced MRI in adults and…
Spyre's SPY002 sets anti-TL1A bar with largest histopathology win in ulcerative colitis
SPY002, Waltham, Massachusetts-based Spyre Therapeutics' (Nasdaq: SYRE) extended half-life anti-TL1A antibody, produced a statistically significant...
Mirum's zilurgisertib becomes first oral therapy to suppress FOP bone formation in Phase II
Pivotal Phase II data from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva (FOP) indicate that the oral ALK2 inhibitor...
Lonza's dual-payload ADC platform advances to clinic with Antharis gastrointestinal cancer deal
Lonza (SIX: LONN) has granted San Diego-based Antharis Therapeutics, Inc. an exclusive, target-specific license to its proprietary dual-payload ADC platform...
Navacaprant's double Phase III failure in depression forces Neumora into strategic reset
Navacaprant's failure to separate from placebo in two consecutive Phase III trials closes the door on kappa opioid receptor antagonism as a near-term...
Prolium brings T-cell engager format to systemic sclerosis
Prolium Bioscience has initiated a first-in-human Phase I trial of PRO-203, a subcutaneously administered CD20×CD3 bispecific T-cell engager, in patients...
Porosome Therapeutics opens India partnership to validate secretory dysfunction theory across six diseases
Boston-based Porosome Therapeutics, Inc. has entered a drug development partnership with India's Council of Scientific and Industrial Research (CSIR), the...
The AllSci Brief
Systematic R&D and deal news. Daily.